Skip to content

A pilot, comparison study of the treatment in acute attack of neuromyelitisoptica: Intravenous methylprednisolone versus plasma exchange alone

A pilot, comparison study of the treatment in acute attack of neuromyelitisoptica: Intravenous methylprednisolone versus plasma exchange alone

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20160314002
Enrollment
10
Registered
2016-03-14
Start date
2016-03-14
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Motor power grade ≤ 2 Medical research council for first attack At least 2&#45

Interventions

intravenous methylprednisolone 1 gram daily for 5&#45
7 days&#44
if no improvement of neurological outcome&#44
add on plasma exchange is performed,Plasma exchange with albumin 1 plasma volume/cycle for 5 cycles (alternating day)
intravenous methylprednisolone,plasma exchange

Sponsors

none
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Diagnosis of neuromyelitis optica/neruomyelitis optica spectrum disorder Admit at siriraj hospital during 2016&#45;2017 Diagnosis of acute severe attack of NMO within 30 days Severe attack was defined at least one of the following Motor power grade ≤ 2 Medical research council for first attack At least 2&#45;point worsening in 1 of the pyramidal of functional system score (FSS) compared to last visit At least 1&#45;point worsening in EDSS score compared to last visit if previous EDSS score is 5.5 or more Visual acuity ≤ 20/200 one eye Glascow coma scale < 6 Hemodynamic instability or respiratory failure

Exclusion criteria

Exclusion criteria: Previous treatment with intravenous steroid Time to next relapse shorter than 90 days Serious / uncontrolled infection Hemodynamic unstable

Design outcomes

Primary

MeasureTime frame
improvement of neurological outcome at discharge and 6 months Expended disability status scale

Secondary

MeasureTime frame
side effect of treatment during the admission&#44; 1 month&#44; 3 months and 3 months side effect

Countries

Thailand

Contacts

Public ContactTayanan Srisupaolan

neurology deparment

tayanans@gmail.com0817788330

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026